预约演示

GRIT and Quangang announce IL-2 T-cell therapy partnership

2024-06-03

细胞疗法临床2期并购基因疗法免疫疗法

The companies will produce a domestically manufactured alternative to the immune-regulating cytokine IL-2 in T-cell therapy. Credit: Anusorn Nakdee/Shutterstock.com.

Clinical-stage cell therapy company Shanghai Grit Biotechnology (GRIT) has formed a strategic partnerIL-2 with Quangang Pharmaceutical (Quangang) to enhance research and development in T-cell therapy for solid tumour patients in China.

Recommended Buyer's Guides

Buyer's GuideShanghai Grit Biotechnology GRIT Quangang Pharmaceutical Quangang solid tumour

Leading Guide to Compliance Software for the Pharmaceutical Industry

Buyer's Guide

Top Guide for Cleanrooms and Cleanroom Flooring

The partnership’s primary goal is to develop a globally standardised IL-2 for solid tumour patients undergoing T-cell therapy.

It will focus on localising this standard with affordable pricing for Chinese patients.

The collaboration will concentrate on broadening the indications of Quanqi (125SER) Interleukin-2 (IL-2) products for solid tumours.

Quanqi (125SER) is a marketed human Interleukin-2 used in treating solid tumours including renal cell carcinoma, breast cancer, melanoma, bladder cancer, colorectal cancer, liver cancer, lymphoma and lung cancer.

See Also:MSD agrees to acquire EyeBio for up to $3bnIL-2 solid tumour

Merck introduces sterility testing solution for pharma quality control

The partnership aims to produce a domestically manufactured alternative to the globaInterleukin-2 (IL-2)une-regulatingsolid tumours2 in T-cell therapy.

GRIT plans to utilise its extensive Interleukin-2 T-cell therapy tosolid tumourshe developmrenal cell carcinomaatbreast cancerhemelanomadubladder cancere colorectal cancer liver cancer lymphoma lung cancer

Both GRITMSDd Quangang believe EyeBioheir joint efforts will soon enable a broader range of Chinese patients to access advanced and effective T-cell treatments, along with an affordable local IL-2 product.

GRIT’s non-gene-engineered tumour infiltrating lymphocytes (TILs) programme, GT101, is in a Phase II (pivotal) trial with plans for a biologics licence application (BLA) filing by 2025.

Merck23 Grit secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.

China International Capital Corporation led the financing round, which saw investments from Qianhai Ark, Liando Group, Yuanhe Capital and HeFangTian Venture Partnership.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.IL-2

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free GRITepaperCell and gene therapies: Pipe dream to pipelineIL-2

The cell and gene industry tumourning momentum, with a new wave of therapies GT101sing to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.

Thank yoGritu will receive an email shortly. Please check your inbox to download the Whitepaper.

By Cytiva ThematicYuanhe Capital

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构